David joined Pharvaris in 2024, bringing more than 30 years of life sciences industry experience in executive financial management roles in development-stage, commercial-stage, public and private companies.

Mr. Nassif serves as Chief Executive Officer, Chief Financial Officer, and Board Member of at Sio Gene Therapies, where he was responsible for all finance, accounting, tax, treasury, legal, and SEC compliance and reporting activities until February 2022, when he undertook the liquidation and dissolution of the company. Prior to joining Sio, Mr. Nassif was Executive Vice President and Chief Financial Officer of SteadyMed Therapeutics, where he was instrumental in its acquisition by United Therapeutics in August 2018. From 2011 to 2014, Mr. Nassif served as the President and Chief Financial Officer of Histogen. Previously, he was Executive Vice President and Chief Financial Officer of Zogenix and held several key roles at Amphastar Pharmaceuticals and RealAge Inc. Earlier in his career, Mr. Nassif held various positions with Cypros Pharmaceuticals, where he was instrumental in leading its merger with Ribogene, Inc. to form Questcor Pharmaceuticals, Inc.

He holds a BS in finance and management information systems with honors from the University of Virginia and a JD from the University of Virginia School of Law.